Brought to you by 
TolerRx gets $31mm in Series D round
05 Apr 2005
Executive Summary
TolerRx (therapies for immune system disorders) brought in $31mm through its Series D round that was led by new investor Bear Stearns Health Innoventures. Other new investor NIF Ventures, new individuals, and existing buyers Skyline Ventures, HealthCare Ventures, Rho Ventures, Vertex Management, Sprout Group, Artal Services, Lehman Brothers, Yasuda Enterprise, Mizuho Capital, Aozora Investment, and Genentech also participated.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TolerRx gets $31mm in Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice